TrialEfficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Trial details
- Registry ID
- NCT04003974
- Phase
- Phase 2
FULC
Fulcrum Therapeutics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
6Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceEvaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension
Trial details
- Registry ID
- NCT04004000
- Phase
- Phase 2
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
Trial details
- Registry ID
- NCT04264442
- Phase
- Phase 2
Losmapimod Safety and Efficacy in COVID-19
Trial details
- Registry ID
- NCT04511819
- Phase
- Phase 3
Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
Trial details
- Registry ID
- NCT05397470
- Phase
- Phase 3
Open-Label Extension Study to Pioneer Study 6058-SCD-101
Trial details
- Registry ID
- NCT07401823
- Phase
- Phase 2
Latest recorded trial changes
Open-Label Extension Study to Pioneer Study 6058-SCD-101
NCT07401823 · Fulcrum Therapeutics
Recruitment status changed
− Before
Not yet recruiting
+ After
Enrolling by invitation
Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension
NCT04004000 · Fulcrum Therapeutics
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Main Study and Extension Study - Treatment-Emergent Adverse Events
+ After
Measure: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Measure: Number of Participants With Clinically Significant Changes in Chemistry Parameters Measure: Number of Participants With Clinically Significant Changes in Hematology Parameters Measure: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters